Specific targeting of activated T cells to treat severe psoriasis vulgaris and generalized pustular psoriasis was first done by using intravenous anti-CD4 monoclonal antibodies.1,2 Improvement occurred; however, a rapid flare was also noted. Recently, systemic treatment with an interleukin 2–diphtheria fusion toxin (DAB389IL-2) was shown to be effective in about 40% of patients with severe psoriasis.3
Mrowietz U, Zhu K, Christophers E. Treatment of Severe Psoriasis With Anti-CD25 Monoclonal Antibodies. Arch Dermatol. 2000;136(5):675–676. doi:
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: